Longchuan Bai
12Patents
6h-index
39Co-inventors
58Inventor score
Filing activity: Jan 24, 2012 → Sep 12, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8691184B2 | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | Chemistry; Metallurgy | 30 | Active |
| US9675697B2 | BET bromodomain inhibitors and therapeutic methods using the same | Chemistry; Metallurgy | 11 | Active |
| US9096625B2 | BCL-2/BCL-XL inhibitors and therapeutic methods using the same | Human Necessities | 10 | Active |
| US10253044B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | Chemistry; Metallurgy | 7 | Active |
| US9403856B2 | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same | Human Necessities | 6 | Active |
| US10391175B2 | BET bromodomain inhibitors and therapeutic methods using the same | Chemistry; Metallurgy | 6 | Active |
| US9580430B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | Chemistry; Metallurgy | 2 | Active |
| US9783539B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | Human Necessities | 1 | Active |
| US11466028B2 | Fused 1,4-oxazepines as BET protein degraders | Human Necessities | 0 | Active |
| US11267822B2 | BET bromodomain protein degraders with cleavable linkers | Chemistry; Metallurgy | 0 | Active |
| US10759808B2 | Monofunctional intermediates for ligand-dependent target protein degradation | Chemistry; Metallurgy | 0 | Active |
| US10633386B2 | BET protein degraders | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.